Acute Leukemias: ClinicalThought™ 2016

CCO’s expert faculty apply their perspectives from the clinic to help you improve outcomes for your patients with acute leukemias.

Share

Program Content

Activities

Recent Progress in AML
Why I Am Optimistic About Recent Progress in AML
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: March 22, 2016

Expires: March 21, 2017

MRD Assessment in ALL
Optimizing MRD Assessment in ALL: Why, How, and When
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: April 22, 2016

Expires: April 21, 2017

Novel Immunotherapies in ALL
Addressing Financial Challenges With Use of New Immunotherapies for Relapsed ALL
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: May 19, 2016

Expires: May 18, 2017

CD123 in AML
Targeting CD123 in AML
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: June 28, 2016

Expires: June 27, 2017

Improving Prospects in AML and ALL
Major Discoveries and the Prospect of Improved Patient Survival in AML and ALL
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: July 26, 2016

Expires: July 25, 2017

Immunotherapy in ALL
How I Interpret Clinical Trial Results to Choose Salvage Immunotherapies for Adult Patients With B-Precursor ALL
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: September 01, 2016

Expires: August 31, 2017

Faculty

cover img faculity

Dan Douer, MD

Associate Professor of Medicine-Hematology
University of Southern California/Norris
Comprehensive Cancer Center and Hospital
Los Angeles, California

cover img faculity

Farhad Ravandi, MD

Professor of Medicine
Department of Leukemia
University of Texas M. D. Anderson Cancer Center
Houston, Texas

cover img faculity

Jonathan Webster, MD

Fellow
Division of Hematologic Malignancies
Department of Oncology
Johns Hopkins University
Baltimore, Maryland

Provided by

ProCE Banner

Supporters

This activity is supported by an educational donation from

Amgen, Inc.